Presence of circulating anti‐c‐<i>myb</i> oncogene product antibodies in human sera

Sorokine, Iréne; Ben-Mahrez, Kamel; Bracone, Annie; Thierry, Dominique; Ishii, Shunsuke; Imamoto, Fumio; Kohiyama, Masamichi

doi:10.1002/ijc.2910470506

Cited by 36 publications

(18 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Development of tumour-associated antibodies against dominant and recessive oncogenes has been observed in several other tumour types (Caron de Fromentel et al, 1987;Ben-Mahrez et al, 1990;Sorokine et al, 1991;Winter et al, 1992;Angelopoulou et al, 1994), and in some cases, the presence of anti-p53 antibodies is …”

Section: Discussionmentioning

confidence: 95%

Serum anti-p53 antibodies in gastric adenocarcinoma patients are associated with poor prognosis, lymph node metastasis and poorly differentiated nuclear grade

Cw¹,

Yang²,

Gd³

et al. 1999

Br J Cancer

View full text Add to dashboard Cite

Summary Mutation of the p53 tumour suppressor gene often leads to the accumulation of mutant p53 protein in tumour cells. Many cancer patients develop antibodies that recognize the overexpressed p53 protein. The presence of these antibodies is, in some tumour types, associated with poor prognosis. Gastric cancer is a highly prevalent disease associated with a high rate of mortality, there is a need for improved clinical and biological markers for disease behaviour. To investigate the clinical relevance of serum anti-p53 antibodies in patients with gastric adenocarcinoma, we have examined the sera of 501 gastric cancer patients for the presence of serum antibodies against the p53 protein. By immunoblotting analysis using a cell lysate containing overexpressed p53 protein as well as affinity-purified recombinant p53 protein as antigens, we have detected anti-p53 antibodies in 11.2% (61 of 501) of gastric cancer patients, but in none of 46 cancer-free individuals. The presence of anti-p53 antibodies was tightly associated with tumours of higher nuclear grade and lymph node metastasis, and a negative association was found between the presence of anti-p53 antibodies and survival. These results suggest that a preoperative test of serum anti-p53 antibodies in gastric cancer patients can be useful to identify subset of patients who may need gastrectomy with lymph node dissection and post-operative adjuvant therapy.

show abstract

Section: Discussionmentioning

confidence: 95%

Serum anti-p53 antibodies in gastric adenocarcinoma patients are associated with poor prognosis, lymph node metastasis and poorly differentiated nuclear grade

Cw¹,

Yang²,

Gd³

et al. 1999

Br J Cancer

View full text Add to dashboard Cite

show abstract

“…Tumour associated autoantibodies bind: Tissue-specific antigens, including tyrosine, actin, galectin-4, and gp756-10 Membrane receptors such as HER-2/neu oncoprotein6 Tissue restricted antigens, such as MAGE and NY-ESO-17 Nuclear proteins such as P53,11 c-myc,12 c-myb,13 DNA topoisomerase II,14 CENP-F,15 and the nucleolar proteins NOR-90/UBF, fibrillarin, and B23 16 …”

Section: Autoantibodies In Patients With Cancermentioning

confidence: 99%

“…Nuclear proteins such as P53,11 c-myc,12 c-myb,13 DNA topoisomerase II,14 CENP-F,15 and the nucleolar proteins NOR-90/UBF, fibrillarin, and B23 16…”

Section: Autoantibodies In Patients With Cancermentioning

confidence: 99%

Cancer and autoimmunity: autoimmune and rheumatic features in patients with malignancies

Abu‐Shakra¹,

Buskila²,

Ehrenfeld³

et al. 2001

Annals of the Rheumatic Diseases

195

134

View full text Add to dashboard Cite

show abstract

“…Antibodies to intracellular, cancer-related proteins such as Myc, Myb and p53 have also been documented. [23][24][25][26][27] Indeed, about 9-15% of breast cancer patients have been found to have circulating antibodies against p53, 23,24 and children with a wide variety of cancers have a similar frequency of p53 antibodies. 28 In the current study, we demonstrate that plasma derived from 14 of 20 Ph-positive CML patients as well as from two of four Ph-negative leukemics and from two of seven normal controls can detect p210 Bcr-Abl .…”

Section: Figurementioning

confidence: 99%

Autoantibodies to Abl and Bcr proteins

et al. 2000

View full text Add to dashboard Cite

Formation of an aberrant, chimeric Bcr-Abl protein is the hallmark of Philadelphia (Ph) chromosome-positive leukemias. The Bcr-Abl protein, as well as its normal cellular counterpartsAbl and Bcr -are intracellular molecules with postulated roles in a variety of critical biologic functions. In this study, we demonstrate the existence of autoantibodies against these proteins. Plasma from 18 of 31 individuals (58%), including 14 of 20 Ph-positive CML patients (70%), two of four normal volunteers (50%), and two of seven patients with Ph-negative leukemia (29%) recognized p210 Bcr-Abl when used in immunoprecipitation followed by immunoblotting experiments. In all 18 patients, plasma was able to recognize baculovirus-expressed Abl protein; in four patients, recognition of baculovirus-expressed Bcr protein was also demonstrated. These observations suggest that a humoral immune response to p210 Bcr-Abl is discernible in both Ph-positive and -negative leukemias and in healthy individuals, and is most likely due to autoantibodies which recognize normal Abl and, to a lesser extent, normal Bcr proteins.

show abstract

Presence of circulating anti‐c‐myb oncogene product antibodies in human sera

Cited by 36 publications

References 31 publications

Serum anti-p53 antibodies in gastric adenocarcinoma patients are associated with poor prognosis, lymph node metastasis and poorly differentiated nuclear grade

Serum anti-p53 antibodies in gastric adenocarcinoma patients are associated with poor prognosis, lymph node metastasis and poorly differentiated nuclear grade

Cancer and autoimmunity: autoimmune and rheumatic features in patients with malignancies

Autoantibodies to Abl and Bcr proteins

Contact Info

Product

Resources

About